Paul Choi

Stock Analyst at Goldman Sachs

(0)
# 4365
Out of 5,329 analysts
138
Total ratings
49.21%
Success rate
-13.04%
Average return
41 Stocks
Name Action PT Current % Upside Ratings Updated
XENE Xenon Pharmaceutical...
Maintains: Buy
60 52
38.18 36.2% 2 Apr 17, 2025
VIR Vir Biotechnology
Maintains: Buy
28 21
6.11 243.7% 8 Apr 17, 2025
URGN UroGen Pharma
Maintains: Neutral
22 16
11.47 39.49% 3 Apr 17, 2025
RGNX Regenxbio
Maintains: Neutral
14 12
9.87 21.58% 3 Apr 17, 2025
PHAT Phathom Pharmaceutic...
Maintains: Neutral
12 10
3.35 198.51% 9 Apr 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 7
1.04 573.08% 5 Apr 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
4 3
0.98 206.12% 9 Apr 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Sell
12 10
11.51 -13.12% 4 Apr 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
15 12
7.24 65.75% 2 Apr 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Sell
20 7
10.99 -36.31% 7 Apr 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
200 225
166.64 35.02% 4 Feb 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
143
106.09 34.79% 1 Dec 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Sell
32 42
49.5 -15.15% 7 Dec 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
85 60
43.03 39.44% 2 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
17 19
14.79 28.47% 6 Aug 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
22 32
27.79 15.15% 1 Jul 26, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
29 50
38.51 29.84% 6 Jul 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
21 19
4.17 355.64% 3 Jun 29, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Sell
16 2
0.34 488.24% 7 Jun 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
29 26
n/a n/a 2 Apr 19, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
29 4
n/a n/a 1 Oct 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
43 25
1 2400% 3 May 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
450 100
n/a n/a 3 May 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
10 4
0.33 1112.12% 4 May 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
25 4
n/a n/a 1 Apr 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
151 170
22.56 653.55% 2 Oct 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
225 125
n/a n/a 2 Sep 22, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Sell
9 8
3.08 159.74% 4 Aug 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
132
n/a n/a 3 Mar 22, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
33
29.38 12.32% 1 Mar 22, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
112
46.24 142.21% 1 Mar 22, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
30
n/a n/a 1 Jan 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
28
n/a n/a 1 Aug 11, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
48 49
n/a n/a 4 Jul 15, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
91 103
n/a n/a 2 Jul 1, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
135
106.71 26.51% 1 Jun 29, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
240
n/a n/a 2 Jun 8, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
5 22
n/a n/a 3 Apr 24, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
18 20
0.78 2464.1% 2 Mar 30, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
58 40
n/a n/a 3 Oct 31, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
60 56
n/a n/a 3 Aug 6, 2018